The MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning technology that will be installed at ZON-PTC operates at unmatched speeds. It can volumetrically scan a typical lung tumor in less than two seconds – eliminating many of the challenges that slower pencil beam scanning solutions encounter. Additionally, Mevion’s Adaptive Aperture technology includes a low-profile micro-multileaf collimator (mMLC) system designed specifically for pencil beam scanning that is capable of delivering the sharpest penumbra physically achievable with protons without the need for manual apertures and adjustments.

Proton therapy provides targeted treatment to cancer tumors and causes less damage to surrounding healthy tissue than traditional photon radiation. As the world’s smallest proton therapy system, the MEVION S250 Series is less than half the size of any other compact system and uses as little as 30% of the energy used by any other compact system, resulting in significantly lower capital, staffing and operating costs. There are currently six centers with operational Mevion proton therapy systems worldwide.

About Mevion Medical System
Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Massachusetts, with a presence in the Europe, Japan and China. For more information, please visit www.mevion.com.


About the MEVION S250 Series
The MEVION S250 Series is elegantly designed to deliver high-powered, efficient proton therapy treatments. Built upon the world’s only gantry-mounted proton accelerator and benefitting from Mevion’s patented direct beam technology, the MEVION S250 Series delivers on the therapeutic promise of proton therapy while enhancing beam quality, stability and uptime. The result is a high-quality treatment with reduced system complexity, higher reliability and throughput, and lower capital and operating costs—making the MEVION S250 Series a compelling, financially viable solution for all cancer centers. The MEVION S250 Series includes:

· MEVION S250 Proton Therapy System®, offering highly stable, next-generation volumetric delivery capabilities

· MEVION S250i Proton Therapy System™ with HYPERSCAN™ with Adaptive Aperture™, overcoming pencil beam scanning uncertainties by delivering robust IMPT treatment at hyper-speed

· MEVION S250mx™, making proton therapy fully scalable, with two, three and four room designs that are inherently redundant and support 100% facility uptime


The MEVION S250i Proton Therapy System with HYPERSCAN with Adaptive Aperture is not yet FDA cleared.

Back to HCB News

Rad Oncology Homepage